Clinical trialNCT06551142RecruitingPhase 1Interventional

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

SponsorGlaxoSmithKlineEnrollment845Neoplasms

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

67 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

Gsk Investigational Site
Rosario, Argentina
Completed
Gsk Investigational Site
Viedma, Argentina
Rubén Kowalyszyn
Recruiting

Canada

Gsk Investigational Site
Hamilton, Ontario, Canada
Courtney Coschi
Recruiting
Gsk Investigational Site
Ottawa, Ontario, Canada
John Hilton
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Albiruni Ryan Ryan Abdul Abdul Razak
Recruiting
Gsk Investigational Site
Montreal, Quebec, Canada
Ramy Saleh
Recruiting
Gsk Investigational Site
Sherbrooke, Quebec, Canada
Michel Pavic
Recruiting

France

Gsk Investigational Site
Bordeaux, France
Antoine Italiano
Recruiting
Gsk Investigational Site
Lyon, France
Philippe Cassier
Recruiting
Gsk Investigational Site
Villejuif, France
Yohann Loriot
Recruiting

Hong Kong

Gsk Investigational Site
Pokfulam, Hong Kong
Thomas Chung-Cheung Yau
Recruiting
Gsk Investigational Site
Shatin, Hong Kong
Herbert Ho Fung Loong
Recruiting

Israel

Gsk Investigational Site
Jerusalem, Israel
Yakir Rottenberg
Recruiting
Gsk Investigational Site
Jerusalem, Israel
Daniela Katz
Recruiting
Gsk Investigational Site
Ramat Gan, Israel
Hadas Gantz Sorotsky
Recruiting
Gsk Investigational Site
Tel Aviv, Israel
Ravit Geva
Recruiting

Italy

Gsk Investigational Site
Milan, Italy
Giuseppe Curigliano
Recruiting
Gsk Investigational Site
Naples, Italy
Adriano Gravina
Recruiting
Gsk Investigational Site
Roma, Italy
Gennaro Daniele
Recruiting
Gsk Investigational Site
Verona, Italy
Andrea Zivi
Recruiting

Japan

Gsk Investigational Site
Aichi, Japan
Kei Muro
Recruiting
Gsk Investigational Site
Chiba, Japan
Shigehiro Koganemaru
Recruiting
Gsk Investigational Site
Shizuoka, Japan
Haruyasu Murakami
Recruiting
Gsk Investigational Site
Tokyo, Japan
Noboru Yamamoto
Recruiting
Gsk Investigational Site
Tokyo, Japan
Shigehisa Kitano
Recruiting

Panama

Gsk Investigational Site
Panama City, Panama
Yong Loo Lau
Recruiting
Gsk Investigational Site
Panama City, Panama
Franklin Castillero
Recruiting

South Korea

Gsk Investigational Site
Gyeonggi-do, South Korea
Young Joo Lee
Recruiting
Gsk Investigational Site
Seoul, South Korea
Jin Seok Ahn
Recruiting
Gsk Investigational Site
Seoul, South Korea
Hye Ryun Kim
Recruiting
Gsk Investigational Site
Seoul, South Korea
Dong-Wan Kim
Recruiting

Spain

Gsk Investigational Site
Badajoz, Spain
Marta González Cordero
Recruiting
Gsk Investigational Site
Barcelona, Spain
Enriqueta Felip Font
Recruiting
Gsk Investigational Site
Barcelona, Spain
Iván Victoria Ruiz
Recruiting
Gsk Investigational Site
Madrid, Spain
Victor Moreno
Recruiting
Gsk Investigational Site
Madrid, Spain
María Eugenia Olmedo García
Recruiting
Gsk Investigational Site
Madrid, Spain
Jon Zugazagoitia Fraile
Recruiting
Gsk Investigational Site
Málaga, Spain
Javier García Corbacho
Recruiting
Gsk Investigational Site
Valencia, Spain
Oscar José Juan Vidal
Recruiting
Gsk Investigational Site
Zaragoza, Spain
Dolores Isla Casado
Recruiting

27 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Bevacizumab →Carboplatin →Cetuximab →Cisplatin →Dostarlimab →Durvalumab →Pembrolizumab →Ris-RezTarlatamab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2024
Primary completion: 16 Oct 2028
Completion: 8 Jun 2029
Last update posted: 22 May 2026
Registered enrollment: 845
Registry id: NCT06551142

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-513663-10

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.